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Background: Intrathecal morphine is commonly used for post caesarean analgesia. However, their use is frequently
associated with the incidence of troublesome side effects such as nausea, vomiting and pruritus. Various mechanisms
have been postulated for the opioid-induced pruritus, with a variety of medications with different mechanisms of
actions formulated for the prevention and treatment. But, the results are inconsistent and hence the prevention and
treatment of opioid-induced pruritus still remains a challenge. Ondansetron which is antiemetic, non-sedative and has
no antianalgesic effect is an antagonist to 5-HT3 receptor, the receptor with which opioids interacts and imparts its
effects. Ondansetron, thus, would be an attractive treatment strategy for both opioid-induced pruritus and post-
operative nausea and vomiting.
Methods: After the approval from institutional review committee and written consent received from the patient, 50
healthy parturients of ASA I and II physical status undergoing caesarean section under spinal anaesthesia were enrolled
for the study. They were randomly categorized into placebo group (2 ml normal saline) and treatment group (2 ml of
4 mg ondansetron), each group containing 25 patients. Pruritus and post-operative nausea and vomiting scores were
recorded up to 24 hours after the administration of intrathecal morphine. Statistical analysis was performed using
chi-square test.
Results: The incidence, severity and necessity of treatment for pruritus in the treatment group was significantly
reduced compared to the placebo group (16% vs 88%). Similarly, the risk of post-operative nausea and vomiting in the
treatment group was less compared to the placebo group (8% vs 56%).
Conclusion: Prophylactic administration of ondansetron to parturients receiving intrathecal morphine for post-
operative analgesia provides a significant reduction of intrathecal morphine-induced pruritus and nausea and vomiting.
Trial registration: CTRI/2015/01/005362 registered on 07/01/2015 in Clinical Trials Registry – India (ctri.nic.in).
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Neuraxial anaesthesia, which includes epidural anaesthesia
and intrathecal anaesthesia, is a frequent anaesthetic ap-
proach for caesarean delivery and other lower abdominal
and lower limb anaesthetic procedures. The addition of
neuraxial morphine to local anaesthetics provides an ef-
fective and prolonged post-operative analgesia. Neuraxial
administration of morphine - an opioid, which is consid-
ered as a gold standard for analgesia, has been associated
with a frequent incidence of pruritus and post-operative
nausea and vomiting (PONV) [1-3]. The incidence of
PONV in patients who received an intrathecal opiate is
60% - 80% [4]. The incidence of neuraxial opioid-induced
pruritus varies widely from 30% - 60% after orthopedic
surgery with intrathecal morphine injection [3,5-7] and
from 60% - 100% in pregnant women after neuraxial opi-
oid administration [3,8-10]. Parturients appear to be the
most susceptible to neuraxial opioid-induced pruritus
which probably might be due to the interaction of oestro-
gens with opioid receptors [8,11]. Although the exact
mechanism of neuraxial opioid-induced pruritus is un-
clear, the postulated mechanisms include the presence of
an “itch centre” in the central nervous system (CNS), me-
dullary dorsal horn activation, antagonism of inhibitory
transmitters, modulation of 5-hydroxytryptamine subtype
3 (5-HT3) or serotonergic pathways and the involvement
of prostaglandins [3,8]. There is dense concentration of
opioid receptors and 5-HT3 receptors in the dorsal part of
the spinal cord and the nucleus of the spinal tract of the
trigeminal nerve in the medulla [8]. Activation of these re-
ceptors by neuraxial opioid administration or by circulat-
ing oestrogen in the parturients results in neuraxial
opioid-induced pruritus which is usually localized to the
face, neck, or upper thorax [7]. Nalbuphine, propofol and
ondansetron have been used effectively in the treatment of
pruritus associated with neuraxial morphine in surgical
patients [12]. In our clinical setting, we undertook a pro-
spective, randomized, double-blinded and placebo con-
trolled study to assess the effectiveness of prophylactic
intravenous (IV) administration of ondansetron in the
prevention of intrathecal morphine-induced pruritus and
PONV.
Methods
This prospective, randomized, double-blinded and placebo
controlled study was conducted at Patan Hospital, Patan,
between August 17, 2008 to January 14, 2009. The institu-
tional review committee of Patan Academy of Health Sci-
ences (IRC-PAHS) approved the study protocol and
written, informed consent was obtained from each patient.
Parturients of American Society of Anesthesiologists
(ASA) class I or II physical status scheduled for caesarean
delivery under spinal anaesthesia were recruited in the
study. Patients with known allergy to ondansetron,morphine or bupivacaine and those with pruritogenic sys-
temic disease, a coexisting skin disorder or preexisting
pregnancy-induced pruritus were excluded from the
study. Similarly, patients with any contraindication for
spinal anaesthesia or those who refused to participate in
the study were also excluded.
Fifty patients were randomly divided into two groups -
P group (placebo group, n = 25) and O group (treatment
group, n = 25). P group received 2 ml of normal saline
whereas O group received 2 ml of a 4 mg ondansetron
IV injection. The study drug (i.e., 2 ml of 4 mg ondanse-
tron) and the placebo (i.e., 2 ml of normal saline) were
prepared by a nurse anaesthetist. She was oriented of
the study procedure but neither involved in the study
nor in the patient care. We used the ondansetron and
normal saline supplied by the pharmaceuticals that were
available in the hospital pharmacy. It was ascertained
that the same manufacturer was used for either drugs in
the study population. The study drugs were given 30 mi-
nutes before administration of spinal anaesthesia. Both
the patients and the anaesthesiologists performing the
spinal anaesthesia and collecting the post-operative data
were blinded as to the study drugs. A nurse anaesthetist
not involved in the study assisted in maintaining the
randomization of sample in a double-blinded fashion,
using a simple lottery method.
IV cannulation was done with 18 gauge cannula and
patients were prehydrated with crystalloid solution
5-10 ml/kg. Spinal anaesthesia was performed at the
level of L3-4 or L4-5 interspace with a 25 gauge
Quincke-type spinal needle using 2.3 ml of 0.5%
(11.5 mg) hyperbaric bupivacaine and 0.2 ml (0.2 mg)
preservative-free morphine mixed in the same syringe.
With constant monitoring of the non-invasive blood
pressure, heart rate and urine output, hydration is main-
tained with crystalloid solution, intra-operatively and
post-operatively for at least 24 hours. Post-operative
wound pain was assessed with a 10-point visual analogue
scale (VAS). Pethedine was used if patient complained of
pain.
Post-anaesthesia care was provided as per the insti-
tutional monitoring protocol. Resident doctors – who
were blinded observers - were involved in the patient
care and data collection in the format provided. The
onset of pruritus was assessed and recorded every
15 minutes for 4 hours along with the complaint by
the patient. Pruritus scores were then evaluated at 4,
8 and 24 hours post-surgery. The degree of pruritis
was categorized as 0 = no pruritus; 1 = mild pruritus;
2 = moderate pruritus; and 3 = severe pruritus. At the
same time, patients were also evaluated for nausea
and vomiting and categorized as 0 = no nausea or
vomiting; 1 = mild nausea; 2 = intense nausea; 3 =
vomiting. 10 mg intravenous metoclopramide was the
Table 2 Incidence of pruritus and post-operative nausea
after cesarean section in placebo and treatment group
Variables
Study group
P-valuePlacebo (P) Treatment (O)
n = 25 (%) n = 25 (%)
Post-operative nausea 14 (56%) 2 (8%) < 0.001
Pruritus 22 (88%) 4 (16%) < 0.001
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(score ≥ 2). For patients with pruritus who requested
the treatment, antihistamines such as pheniramine
maleate and μ-opioid receptor antagonists such as na-
loxone were used depending upon the severity
assessed by the clinician, if required.
A power analysis showed that 21 patients in each
group would be sufficient to detect a difference of 60%
pruritus incidence between the treatment and placebo
group with a power of 95% and at 1% significance level.
The perceived pruritus incidence difference between
treatment and placebo group was derived from the study
of Yeh et al. [9] where pruritus incidence in treatment
group (p1) = 0.25 and pruritus incidence in placebo
group (p2) = 0.85. Statistical analysis of the results was
performed using chi-square test to compare the categor-
ical variables. Data are also presented in mean with
standard deviation and percentage.
Results
All 50 patients were enrolled in the study during the
period of five months and all the patients enrolled par-
ticipated until the completion of the study. The demo-
graphic data of the patients involved in the study were
tabulated in Table 1.
Post-surgery pruritus occurred in 88% of the pa-
tients who received the placebo injection whereas
only 16% of the patients who received 4 mg of
ondansetron prophylactically developed pruritus. Simi-
larly, 56% of the patients in the placebo group com-
plained of post-operative nausea whereas only 8% of
the patients in the treatment group complained of
post-operative nausea. The incidence of pruritus and
post-operative nausea in the study groups are statisti-
cally significant (p < 0.001) and illustrated in Table 2.
However, the onset and the duration of pruritus in
both the groups, as shown in Table 3, were similar
and statistically insignificant (P > 0.05). The difference
in the severity of pruritus scores in both groups was
statistically significant (P < 0.001) as shown in Figure 1.
There were no patients with severe pruritus in either
group. In the P group, 8% of cases (n = 2) had moder-
ate pruritus, whereas no patient in the O group had




Placebo (P) Treatment (O)
n = 25 n = 25
Age (yrs) 25.2 ± 3.27 24.2 ± 3.56
Height (cm) 157.4 ± 4.77 155 ± 4.12
Weight (kg) 69.2 ± 9.96 70.8 ± 8.56the cases required any sort of medications to treat
the pruritus.
The incidence of post-operative nausea was also sig-
nificantly different (P < 0.001) between the P group
(56%) and O group (8%). The severity scores of post-
operative nausea in both the groups were also statisti-
cally significant (P < 0.001) as shown in Figure 2.
There were no cases of vomitting in either of the
groups. O group had a smaller incidence of both mild
and intense post-operative nausea (4% each) whereas
in P group the incidence for mild post-operative nau-
sea and intense post-operative nausea was higher at
36% and 16%, respectively. All patients with intense
post-operative nausea were treated with 10 mg IV
metoclopramide.
As per the institutional protocol for patient care,
pethedine was our choice of treatment if the study popu-
lation complained of unbearable pain. We did not have
any case that needed pethedine to manage the pain com-
plained by the patients during our study period, prob-
ably due to the analgesic property of intrathecal
morphine. However, acetaminophen 500 mg per rectal
suppository was used at times – 3 cases in O group and
5 cases in P group, during 24 hours of observation. The
data on pain scores and pain management were not in-
cluded in this study as the prime objective of the study
was not pain management.
There were no patients who were hypotensive intra-
operatively or post-operatively. It is because vitals are
continuously monitored and managed immediately upon
requirement. Similarly, there were no profuse bleeding
cases that lead to hypotension. Besides, crystalloids were
used, whenever required, with continuous monitoring of
vitals. Therefore, data on vitals such as blood pressure
and heart rate were not mentioned in the manuscript.
Discussion
Morphine, an opioid, is an alkaloid constituent of opium.
It is the dried latex obtained as natural product in opium
poppy (Papaver somniferum). Morphine is an archetypal
opioid which, in clinical medicine, is still considered as a
mainstay of analgesic therapy used to relieve intense
pain and suffering. It elicits analgesia by stimulating the
opioid receptors, a G protein-coupled receptor (GPCR)
highly expressed in the central nervous system [13].
Table 3 Onset and duration of pruritus
Variables
Study group
P-valuePlacebo (P) Treatment (O)
Mean ± SD Mean ± SD
First occurrence of pruritus in hours (after admission of intrathecal morphine) 2.64 ± 0.456 2.96 ± 0.334 >0.05
Duration of pruritus (itching) in hours 12.82 ± 0.56 14.25 ± 0.50 >0.05
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chronic pain, morphine induces various side effects such
as nausea, vomiting and more importantly pruritus upon
neuraxial injection [11,14]. Pruritus - an unpleasant and
irritating sensation leading to scratching - is a common
adverse effect of neuraxial morphine with the highest
prevalence (up to 100%) associated with intrathecal mor-
phine administration [11]. It is generally mild and local-
ized to the face and trunk, but it can be severe and
cause significant maternal discomfort [15]. Despite its
frequent occurrence and practice of utilizing various
pharmacological therapies including antihistamines, 5-
HT3 receptor antagonists, opiate antagonists, propofol
(hypnotic agent), non-steroidal anti-inflammatory drugs
(NSAIDS) and anti-dopaminergic drugs, there are no
consistently effective therapies established for opioid-
induced pruritus [3,11,16].
Pruritus caused by opioids develops shortly after an-
algesia and the prevalence, onset time, duration and
severity depends on the type, route and dosage of
opioid used. Lipid soluble opioids, such as fentanyl
and sufentanil invoke pruritus of shorter duration.
The use of the minimum effective dose of such opi-
oids and the addition of local anaesthetics seems to
decrease the prevalence and the severity of pruritus.
Pruritus induced by intrathecal administration of mor-
phine is of longer duration and difficult to treat.
Intrathecal administration of opioids reaches the peak
concentrations in the cerebrospinal fluid (CSF) almost







Placebo (P) Treatment (O)
Figure 1 Pruritus severity.In epidural administration of opioids, the rise to peak
concentration in CSF is relatively delayed (10–20 mi-
nutes with fentanyl and 1–4 hours with morphine)
[3]. Furthermore, the epidural space contains an ex-
cessive venous plexus which assists in extensive vas-
cular reabsorption of opioids administered epidurally.
Therefore, the side effect of opioids such as pruritus
is more common and intense in intrathecal morphine
administration than in epidural administration [17].
Though pruritus is considered as the most common
side effect of neuraxial administration of opioids, with
the reported incidence between 30% and 100%, the
exact mechanism behind the neuraxial opioid induced
pruritus is yet unclear [14]. It is probably not related
to histamine release since antihistamines are ineffect-
ive in the therapy of pruritus caused by neuraxial
morphine [18] and, as well, other opioids such as fen-
tanyl and sufentanil that do not release histamine also
cause pruritus when administered into the neuraxis
[19]. Another theory proposes that opioid receptors
that are located both supraspinally and at the spinal
cord level are activated by morphine. The μ receptor
is mainly responsible for pain modulation and some
side effects, especially pruritus and nausea or vomit-
ing which explains the antipruritic effects of μ antag-
onists such as nalbuphine and naloxone [12,20].
Thirdly, pruritus from neuraxial opioids may also be
related to the excitatory effects of opioids on the
nocifensive and non-nocifensive neurons in the anter-
ior and posterior spinal horns [21]. Propofol, which











Placebo (P) Treatment (O)
Figure 2 Post-operative nausea severity.
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induced pruritus [22]. Lastly, the evidences from vari-
ous studies and clinical practice for the treatment of
postoperative nausea, vomiting and pruritus have
strongly proposed 5-HT3 receptor interaction by opi-
oids as a probable mechanism [12,14]. Fan has re-
ported that morphine can activate 5-HT3 receptors
by a mechanism independent of opioid receptors [23]
which implies the direct stimulation of 5-HT3 recep-
tors in the dorsal horn of the spinal cord and in the
medulla by intrathecal morphine injection possibly
leading to pruritus [12]. 5-HT3 receptors are abun-
dant in the dorsal horn of the spinal cord and the
spinal tract of the trigeminal nerve in the medulla
[14]. 5-HT3 receptor antagonists, such as ondanse-
tron, are effective in the prevention and treatment of
PONV [24,25]. Studies have also shown that 5-HT3
receptor antagonists significantly reduced the risk of
pruritus compared to placebo whereas some studies
showed no significant differences, thus creating the
conflict regarding the efficacy of prophylactic 5-HT3
receptor antagonists in neuraxial opioid-induced prur-
itus prevention [4,7,9,12,14,24,26]. A metaanalysis by
George et al. suggests that prophylactic 5-HT3 recep-
tor antagonists were ineffective in reducing the inci-
dence of pruritus but significantly effective in
reducing the severity and the need for treatment of
pruritus in parturients who received intrathecal mor-
phine for cesarean delivery. They were also effective
for the treatment of established pruritus. However,
more studies are recommended to settle the conflict
regarding the efficacy of prophylactic 5-HT3 receptor
antagonists in neuraxial opioid-induced pruritus pre-
vention [25]. We, thus, intended to assay in our study
the efficacy of prophylactic administration of 5-HT3
receptor antagonist ondansetron in the prevention of
intrathecal morphine induced pruritus and PONV.
We chose the dose of 4 mg of ondansetron as it has
been proven successful in the treatment of intrathecal
morphine-induced pruritus [12,27]. However, the dose
of 4–8 mg or 0.1 mg kg−1 are also in practice [9,14].
Additionally, other 5-HT3 antagonists, such as tropi-
setron, granisetron and dolasetron are also used [14].
This study showed that the incidence of pruritus after
intrathecal morphine injection in patients undergoing
cesarean delivery was frequent (88%) which can be
prophylactically managed by IV administration of ondan-
setron, which was similar to the study done by Yeh et al.
[9]. On the other hand, the incidence of PONV can, as
well, be effectively managed prophylactically by injection
of ondansetron. However, for those patients who devel-
oped pruritus, the onset and duration were similar in
both groups. Although IV ondansetron significantly re-
duced the incidence of intrathecal morphine-inducedpruritus, this complication still occurred in approxi-
mately 16% of the patients, which suggests that these pa-
tients might need other treatment regimens such as
naloxones (opioid receptor antagonists) or propofol (an-
tagonist to excitatory effect on the dorsal horn of the
spinal cord). However, we limited our study to a single
type of 5-HT3 antagonist i.e., ondansetron with a fixed
dose of 4 mg. Hence, a study examining dose-dependent
effects and with 5-HT3 antagonists of different potency
would be worthwhile to conduct in the future in this
population.
Conclusion
Nausea, vomiting and pruritus are the common side
effects of intrathecal morphine administration as a
part of spinal anaesthesia for the patients undergoing
caesarean delivery. However, it can be efficiently man-
aged by IV administration of 4 mg ondansetron 30 mi-
nutes prior to intrathecal morphine injection. In our
study, it significantly reduced the incidence, severity
and the need for treatment of pruritus and post-
operative nausea.
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